Thursday, March 20, 2025 3:34:12 PM
For a company this size and with limited complexity, they're likely looking somewhat less than that (their ongoing rate would probably start out in the $25k range, but the initial may be significantly higher).
The penny threshold is really the limiting factor. If they could somehow generate the revenue/validate their projections to support that PPS, the audit fees would become secondary.
The penny threshold is really the limiting factor. If they could somehow generate the revenue/validate their projections to support that PPS, the audit fees would become secondary.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
